Impact of Chemotherapy on Ovarian Reserve in Young Women With Breast Cancer (Resova)
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Bordeaux, France, 33076
- Institut Bergonie
-
Caen, France, 14076
- Centre François Baclesse
-
Clermont-Ferrand, France, 63011
- Centre Jean Perrin
-
Dijon, France, 21079
- CRLC de Bourgogne Georges François Leclerc
-
Lille, France, 59000
- Centre Oscar Lambret
-
Lyon, France, 69373
- Centre de lutte contre le cancer Léon Bérard
-
Montpellier, France, 34098
- Centre Val d'Aurelle - Paul Lamarque
-
Paris, France, 75005
- Institut Curie
-
Reims, France, 51056
- Institut Jean Godinot
-
Rennes, France, 35042
- Centre Eugene Marquis
-
Saint Herblain, France, 44805
- Centre de Lutte Contre le Cancer Nantes Atlantique René Gauducheau
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- female 18-39 years
- suffering from breast cancer
- treated with adjuvant or neoadjuvant chemotherapy
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
young women with breast cancer
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To evaluate the effects of adjuvant or neoadjuvant chemotherapy treatment on ovarian reserve for in situ breast cancer patients
Time Frame: 24 months
|
Serum anti-Müllerian hormone concentration will be measured at each chemotherapy administration and 24 months follow-up after chemotherapy completion
|
24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Paul Barrière, MD, Nantes university hospital
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- BRD/09/06-J
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.